First-quarter 2024 total net sales were $610.8 million, a decrease of 9.8 percent compared to $676.8 million reported for the first quarter of 2023...
Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today ...
Broad-based performance drives sales, profits and earnings growth: Total Q1 2024 sales £7.4 billion +10% and +13% ex COVID Vaccines sales +16...
Q1 2024: Net sales of $459 million (-5% actual rates, -5% constant exchange rates, CER); diluted EPS of $0.36 and adjusted diluted EPS of $0.46 Net ...
Gilead Sciences Announces First Quarter 2024 Financial Results Product Sales Excluding Veklury Increased 6% Year-Over-Year to $6.1 billion Biktarvy...
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, reported its financial results for the first quarter ended March 30, ...
Under Narasimhan's leadership, the company sees significant sales and profit growth across major products, prompting an upward revision of the full-year 20...
Financial results of fiscal 2023 Net sales decrease organically by 1.6% to € 21.0 billion EBITDA pre down organically by 9.0% to € ...
ICON plc (NASDAQ:ICLR), a global leader in healthcare intelligence and clinical research, announced its financial results for the fourth quarter and ...
Bio-Rad Laboratories Inc. reports a 6.7% decrease in fourth-quarter net sales compared to 2022, largely attributed to ongoing weakness in biopharma markets...
-IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a global leader in advanced analytics, technology solutions, and clinical research services ...
Q2'24 net revenue of $1.03 billion decreased 10% as reported, or 11% in constant currency(1), compared to Q2'23. Q2'24 net revenue, excluding COVID...
Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") disclosed its financial performance for the fourth quarter and fiscal year 2023, includin...
Key Points: AstraZeneca announces robust financial performance for the full year and fourth quarter of 2023, marked by strong revenue growth and s...
© 2024 Biopharma Boardroom. All Rights Reserved.